Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
The main aim of this study is to compare the prognostic value of R-IPI at diagnosis and relapse, relating it with the obtained response after second line
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 \> years old
Patients with refractory/relapsed diffuse large B-cell lymphoma after first line treatment with rituximab, with or without transplantation. Patients must have finished a rescue treatment including rituximab
Ability to understand and willingness to sign a written informed consent
